Gopal, Ajay K.;
Chen, Robert;
Smith, Scott E.;
Ansell, Stephen M.;
Rosenblatt, Joseph D.;
Savage, Kerry J.;
Connors, Joseph M.;
Engert, Andreas;
Larsen, Emily K.;
Chi, Xuedong;
Sievers, Eric L.;
Younes, Anas
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Contributor:
Gopal, Ajay K.;
Chen, Robert;
Smith, Scott E.;
Ansell, Stephen M.;
Rosenblatt, Joseph D.;
Savage, Kerry J.;
Connors, Joseph M.;
Engert, Andreas;
Larsen, Emily K.;
Chi, Xuedong;
Sievers, Eric L.;
Younes, Anas
Published:
American Society of Hematology, 2015
Published in:
Blood, 125 (2015) 8, Seite 1236-1243
Language:
English
DOI:
10.1182/blood-2014-08-595801
ISSN:
0006-4971;
1528-0020
Origination:
University thesis:
Footnote:
Description:
<jats:title>Key Points</jats:title>
<jats:p>A total of 47% of patients who achieved CR on brentuximab vedotin remain progression-free after being followed a median of 53 months. Younger age, less functional impairment, and lower disease burden at baseline were associated with CR and prognostic for longer survival.</jats:p>